Hyperthyroidism in a 15-year-old adolescent treated with Dupilumab for severe allergic asthma and atopic dermatitis

• Maria Angela Tosca ^[1] ; Roberta Olcese ^[1] ; Donata Girosi ^[2] ; Emilio Casalini ^[3] ; Marco Scaglione ^[1] ; Giorgio Ciprandi ^[4]
  1. [1] Allergy Clinic, IRCCS Giannina Gaslini, Genoa, Italy.
  2. [2] Pediatric Pulmonology and Respiratory Endoscopy, IRCCS Giannina Gaslini, Genoa, Italy.
  3. [3] Pediatric Clinic and Endocrinology, IRCCS Giannina Gaslini, Genoa, Italy.
  4. [4] Allergy Clinic, Casa di Cura Villa Montallegro, Genoa, Italy.

  Mostrar afiliaciones +
• Localización: Allergologia et immunopathologia: International journal for clinical and investigate allergology and clinical immunology, ISSN-e 1578-1267, ISSN 0301-0546, Vol. 51, Nº. 3, 2023, págs. 181-185
• Idioma: inglés
• Enlaces
  • Texto completo
• Resumen

  • Dupilumab is a biologic, acting on IL-4 and IL-13 pathways. Dupilumab has a pediatric indication for treating severe asthma and atopic dermatitis. We report a pediatric case concerning paucisymptomatic, transient, and self-resolving hyperthyroidism. The updated literature includes the case of an adult patient who reported with hyperthyroidism, which was transient and self-resolving. Despite that these cases were transient and self-resolving, we would suggest that thyroid function assessment could be included in the follow-up of patients treated with Dupilumab. Dupilumab discontinuation is not required pending endocrinological assessment, mainly if there is an optimal clinical response to the biologic.